CN114805301B - 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 - Google Patents
2,4-二芳氨基嘧啶类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114805301B CN114805301B CN202210475888.9A CN202210475888A CN114805301B CN 114805301 B CN114805301 B CN 114805301B CN 202210475888 A CN202210475888 A CN 202210475888A CN 114805301 B CN114805301 B CN 114805301B
- Authority
- CN
- China
- Prior art keywords
- amino
- alkyl
- cancer
- acid
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 7
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 4
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 3
- 206010018338 Glioma Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 229910001416 lithium ion Inorganic materials 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229910001415 sodium ion Inorganic materials 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229940126069 ALK kinase inhibitor Drugs 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 abstract description 16
- 239000000651 prodrug Substances 0.000 abstract description 8
- 229940002612 prodrug Drugs 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 239000012453 solvate Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- -1 dithiocarbamic acid ester Chemical class 0.000 description 80
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 40
- 125000000217 alkyl group Chemical group 0.000 description 35
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 29
- 229910052739 hydrogen Inorganic materials 0.000 description 29
- 239000001257 hydrogen Substances 0.000 description 29
- 238000006467 substitution reaction Methods 0.000 description 26
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 150000002431 hydrogen Chemical class 0.000 description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 12
- 229960001602 ceritinib Drugs 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 102220197960 rs1057519783 Human genes 0.000 description 3
- 102220197961 rs1057519784 Human genes 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- GWQWBFBJCRDINE-UHFFFAOYSA-M sodium;carbamodithioate Chemical class [Na+].NC([S-])=S GWQWBFBJCRDINE-UHFFFAOYSA-M 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 101150023956 ALK gene Proteins 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 229950004394 ditiocarb Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 description 1
- 108700009251 p80(NPM-ALK) Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药领域，涉及通式I所示的2,4‑二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药，它们的制备方法和含有所述化合物的药物组合物及应用，其中取代基L、X、Y、Ra具有在说明书中给出的含义。本发明还涉及通式I的化合物在制备用于治疗和/或预防ALK介导的疾病药物中的应用，特别是在制备治疗淋巴瘤、非小细胞肺癌、小细胞肺癌、神经胶质瘤、成神经细胞瘤等的药物中的应用。
Description
技术领域:
本发明属于医药领域，涉及2,4-二芳氨基嘧啶类ALK抑制剂及其立体异构体以及药学上可接受的盐、它们的制备方法和含有所述化合物的药物组合物以及这类化合物或药物组合物在制备抗肿瘤药物中的应用。
背景技术：
间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)为胰岛素受体酪氨酸激酶家族中的一员，以NPM-ALK融合基因的形式在间变性大细胞淋巴瘤(anaplastic largecell lymphoma,ALCL)中首次被发现，是一种由1620个氨基酸组成，包括胞外配体结合域、跨膜域及胞内酪氨酸激酶结构域的跨膜蛋白。ALK可激活多个细胞内信号通路，包括磷脂酶Cγ、JAK激酶、信号转导和转录激活因子(signaltransducer and activator oftranscription-3,STAT3)、磷脂酰肌醇-3-激酶(phosphatidylinositol 3-kinase,PI3K)、哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)及丝裂原活化蛋白激酶(mitogen-activated protein kinase，MAPK)等，参与调节细胞生长、转化及抗细胞凋亡。在多种肿瘤中均发现了ALK基因重组、突变或扩增，包括淋巴瘤、神经母细胞瘤及非小细胞肺癌(non-small cell lung cancer，NSCLC)。截至目前，已有21个不同的基因被发现与ALK发生易位，不同的ALK融合蛋白可能引起不同信号通路的激活，导致癌细胞的增殖速率、侵袭及致瘤能力均不同。因此，靶向ALK抑制剂可以通过抑制ALK下游相关信号而达到抗肿瘤的目的。
Ceritinib是由诺华研发的第二代ALK抑制剂，于2014年4月29日经美国FDA批准上市。该药用于治疗ALK阳性、肿瘤病情有进展或不能耐受Crizotinib的转移性非小细胞肺癌患者。然而，随着在临床上的长期应用，大部分患者亦不可避免地对Ceritinib产生了耐药，超过半数耐药患者体内出现了ALK耐药突变。因此开发新型的抗ALK耐药突变的抑制剂迫在眉睫。
二硫代氨基甲酸酯是一类已报道具有较好抗肿瘤活性的片段，我们通过分子杂交的设计策略，在Ceritinib的哌啶端直接或通过linker引入二硫代氨基甲酸酯片段，发现了具有抗Ceritinib耐药突变的ALK抑制剂。
发明内容：
本发明涉及通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药。通式I为：
其中，L独立选自6–10元芳基、5–12元杂芳基、(C0–C8)烷基、(C2–C8)烯基、(C2–C8)炔基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基、芳基(C1–C6)烷基、杂芳基(C1–C6)烷基；所述的6–10元芳基、5–12元杂芳基、(C0–C8)烷基、(C2–C8)烯基、(C2–C8)炔基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基、芳基(C1–C6)烷基、杂芳基(C1–C6)烷基可被1–3个R1取代；
R1独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、羧基、氨基；
X、Y选自S、(C0–C4)烷基；
Ra独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、羧基、氨基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；
R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、氨基、羧基、–(C＝O)NR3R4或–NR3R4；
R3、R4独立地选自氢、(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基、氨基磺酰基(C1–C4)烷基、甲磺酰氨基(C1–C4)烷基、羧基(C1–C4)烷基；所述(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基、氨基磺酰基(C1–C4)烷基、甲磺酰氨基(C1–C4)烷基、羧基(C1–C4)烷基可任选被1–3个R5取代；
或者R3、R4和与它们相连的氮原子一起形成一个3–10元的含氮杂环，优选为5–6元含氮杂环；所述的含氮杂环含有0–3个选自N、O或S的杂原子，任选包括0～2个碳碳双键或叁键；所述的含氮杂环可任选被1–3个R6取代；
R5、R6独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、(C3–C8)环烷基、氰基、羟基、羧基、氨基。
本发明优选涉及通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药。
其中，L独立选自(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基；所述的(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基可被1–3个R1取代；
R1独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基；
X、Y选自S、(C0–C4)烷基；
Ra独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；
R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、氨基、羧基、–(C＝O)NR3R4或–NR3R4；
R3、R4独立地选自氢、(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基；所述(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基可任选被1–3个R5取代；
或者R3、R4和与它们相连的氮原子一起形成一个3–10元的含氮杂环，优选为5–6元含氮杂环；所述的含氮杂环含有0–3个选自N、O或S的杂原子，任选包括0～2个碳碳双键或叁键；所述的含氮杂环可任选被1–3个R6取代；
R5、R6独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、(C3–C8)环烷基、羟基、氨基。
本发明还优选涉及通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药。
其中，L独立选自(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基；所述的(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基可被1–3个R1取代；
R1独立地选自氢、(C1–C4)烷基；
X、Y选自S、(C0–C4)烷基；
Ra独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；
R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基、羧基、–(C＝O)NR3R4或–NR3R4；
–(C＝O)NR3R4或–NR3R4中的–NR3R4选自：
本发明更加优选涉及通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药。
其中，L独立选自(C0–C4)烷基、(C1–C4)烷基甲酰基、氨基(C1–C4)烷基；所述的(C0–C4)烷基、(C1–C4)烷基甲酰基、氨基(C1–C4)烷基可被1–3个R1取代；
R1独立地选自氢、(C1–C4)烷基；
X、Y选自S、(C0–C2)烷基；
Ra独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；
R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基、–(C＝O)NR3R4或–NR3R4；
–(C＝O)NR3R4或–NR3R4中的–NR3R4选自：
本发明特别优选涉及通式I的化合物及其立体异构体、药学上可接受的盐、溶剂化物或其前药，其中，L为(C0–C2)烷基、氨基(C2–C3)烷基、(C1–C3)烷基甲酰基；
X、Y为S、(C0–C2)烷基；
Ra为–NR3R4、–(CH2)2NR3R4、–(CH2)3NR3R4、–(C＝O)NR3R4、–(CH2)2(C＝O)NR3R4、–(CH2)3(C＝O)NR3R4；
–NR3R4为：
本发明通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐、溶剂化物或其前药选自以下化合物，但这些化合物并不意味着对本发明的任何限制：
以上所述的通式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐，所述的药学上可接受的盐包括与无机酸、有机酸、碱金属离子形成的盐；所述的无机酸选自：盐酸、氢溴酸、氢氟酸、硫酸、磷酸；所述的有机酸选自：琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、甲磺酸、乙磺酸或对甲苯磺酸；所属的碱金属离子选自锂离子、钠离子或钾离子。
此外，本发明还包括本发明化合物的前药。本发明化合物的前药是通式I的衍生物，它们自身可能具有较弱的活性甚至没有活性，但是在给药后，在生理条件下(例如通过代谢、溶剂分解或另外的方式)被转化成相应的生物活性形式。
本发明中“卤素”是指氟、氯、溴或碘；“烷基”是指直链或支链的烷基；“杂芳基”是指含有碳原子和杂原子的单环或多环的环状体系，且环状体系具有芳香性，杂原子的种类和数目如权利要求所述；代表取代基连接处。
本发明所述通式I所述化合物中，L独立选自6–10元芳基、5–12元杂芳基、(C0–C8)烷基、(C2–C8)烯基、(C2–C8)炔基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基、芳基(C1–C6)烷基、杂芳基(C1–C6)烷基；所述的6–10元芳基、5–12元杂芳基、(C0–C8)烷基、(C2–C8)烯基、(C2–C8)炔基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基、芳基(C1–C6)烷基、杂芳基(C1–C6)烷基可被1–3个R1取代；
其中，R1独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、羧基、氨基；R1为任意位置取代。
本发明所述L有两个键合位，分别与Ceritinib哌啶上的N和X键合，例如，C1烷基实际指亚甲基–CH2–。
本发明所述“(C0–C8)烷基”中C0烷基实际指通式I所述化合物中，Ceritinib哌啶上的N直接与X键合。其他基团涉及C0的表达均为此含义。
本发明所述L中，“氨基(C1–C8)烷基”指“–NH–(C1–C8)烷基”，且–NH–侧键合X。例如，“氨基C2烷基”为“–NH–CH2–CH2–”。其他涉及类似表达方式的均为此含义。例如，“(C1–C8)烷基甲酰基”指“(C1–C8)烷基–CO–”；“C2烷基甲酰基”指“–CH2–CH2–CO–”，其中–CH2–侧键合X。
优选地，L独立选自(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基；所述的(C0–C8)烷基、(C1–C8)烷基甲酰基、氨基(C1–C8)烷基可被1–3个R1取代；进一步优选地，L独立选自(C0–C4)烷基、(C1–C4)烷基甲酰基、氨基(C1–C4)烷基；所述的(C0–C4)烷基、(C1–C4)烷基甲酰基、氨基(C1–C4)烷基可被1–3个R1取代。
优选地，R1独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基；进一步优选地，R1独立地选自氢、(C1–C4)烷基。
最优选地，L为(C0–C2)烷基、氨基(C2–C3)烷基、(C1–C3)烷基甲酰基，具体地，L为C0(即Ceritinib哌啶上的N直接与X键合)、–CH2、–CH2–CH2–、–NH–CH2–CH2–、–NH–CH2–CH2–CH2–、–CH2–CO–、–CH2–CH2–CO–或–CH2–CH2–CH2–CO–。
本发明所述通式I所述化合物中，X、Y选自S、(C0–C4)烷基。
本发明所述X有两个键合位，分别与L和碳键合，X的可选基团上的两个H原子分别被L和碳所取代。本发明所述Y有两个键合位，分别与碳和Ra键合，Y的可选基团上的两个H原子分别被Ra和碳所取代。
优选地，X、Y选自S、(C0–C2)烷基，具体地，X选自S、X为C0(即L直接与碳硫双键的碳键合)、–CH2、–CH2–CH2–；Y选自S、Y为C0(即L直接与碳硫双键的碳键合)、–CH2、–CH2–CH2–。
本发明所述通式I所述化合物中，Ra独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、羧基、氨基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；
本发明所述Ra有一个键合位。例如，“C1烷基”指“–CH3”。
优选地，Ra独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代；进一步优选地，Ra独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基；所述的(C1–C4)烷基、(C1–C4)烷氧基可任选被1–3个R2取代。R2为任意位置取代。
本发明所述通式I所述化合物中，R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、氰基、羟基、氨基、羧基、–(C＝O)NR3R4或–NR3R4；进一步优选地，R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基、羧基、–(C＝O)NR3R4或–NR3R4；更进一步优选R2独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、羟基、氨基、–(C＝O)NR3R4或–NR3R4；
本发明所述通式I所述化合物中，R3、R4独立地选自氢、(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基、氨基磺酰基(C1–C4)烷基、甲磺酰氨基(C1–C4)烷基、羧基(C1–C4)烷基；所述(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基、氨基磺酰基(C1–C4)烷基、甲磺酰氨基(C1–C4)烷基、羧基(C1–C4)烷基可任选被1–3个R5取代；R5为任意位置取代。
本发明所述R3、R4中，所述“羟基(C1–C4)烷基”指羟基任意取代的烷基，如“羟基C2烷基”指“–CH2–CH2–OH”。所述氨基(C1–C4)烷基、氨基磺酰基(C1–C4)烷基、甲磺酰氨基(C1–C4)烷基、羧基(C1–C4)烷基”分别为氨基取代的(C1–C4)、氨基磺酰基取代的(C1–C4)、甲磺酰氨基取代的(C1–C4)、羧基取代的(C1–C4)。例如，“氨基C2烷基”为“–CH2–CH2–NH2”。
或者R3、R4和与它们相连的氮原子一起形成一个3–10元的含氮杂环，优选为5–6元含氮杂环；所述的含氮杂环含有0–3个选自N、O或S的杂原子，任选包括0～2个碳碳双键或叁键；所述的含氮杂环可任选被1–3个R6取代。R6为任意位置取代。
优选地，R3、R4独立地选自氢、(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基；所述(C1–C4)烷基、(C3–C8)环烷基、羟基(C1–C4)烷基、氨基(C1–C4)烷基可任选被1–3个R5取代；
或者R3、R4和与它们相连的氮原子一起形成一个3–10元的含氮杂环，优选为5–6元含氮杂环；所述的含氮杂环含有0–3个选自N、O或S的杂原子，任选包括0～2个碳碳双键或叁键；所述的含氮杂环可任选被1–3个R6取代；
本发明所述通式I所述化合物中，R5、R6独立地选自氢、卤素、(C1–C4)烷基、(C1–C4)烷氧基、(C3–C8)环烷基、氰基、羟基、羧基、氨基；优选地，R5、R6独立地选自氢、(C1–C4)烷基、(C1–C4)烷氧基、(C3–C8)环烷基、羟基、氨基。
最优选地，Ra为–NR3R4、–(CH2)2NR3R4、–(CH2)3NR3R4、–(C＝O)NR3R4、–(CH2)2(C＝O)NR3R4、–(CH2)3(C＝O)NR3R4。
更进一步地，–(C＝O)NR3R4或–NR3R4中的–NR3R4选自：
更进一步地，–(C＝O)NR3R4或–NR3R4中的–NR3R4选自：
更进一步地，–NR3R4为：
本发明可以含有上式I的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐作为活性成分，与药学上可接受的载体或赋形剂混合制备成组合物，所述载体或赋形剂包括本领域公知的稀释剂、粘合剂、润湿剂、崩解剂、润滑剂、助流剂等。稀释剂包括但不限于淀粉、糊精、蔗糖、葡萄糖、乳糖、甘露醇、山梨醇、木糖醇、磷酸氢钙等；湿润剂包括水、乙醇、异丙醇等；粘合剂包括但不限于淀粉浆、糊精、糖浆、蜂蜜、葡萄糖溶液、阿拉伯胶浆、明胶浆、羧甲基纤维素钠、羟丙基甲基纤维素、乙基纤维素、聚乙二醇等；崩解剂包括但不限于干淀粉、微品纤维素、低取代羟丙基纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠、羧甲基淀粉钠、十二烷基磺酸钠等；润滑剂和助流剂包括但不限于滑石粉、二氧化硅、聚乙二醇等。
本发明的药用组合物可配制成若干种剂型，所述剂型包括但不限于注射剂、片剂、胶囊剂等。
本发明的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐可以与其他活性成分组合使用，从而达到更优的治疗效果。
本发明的2,4-二芳氨基嘧啶类化合物及其立体异构体以及药学上可接受的盐可以用于预防或治疗淋巴瘤、非小细胞肺癌、小细胞肺癌、头颈部细胞癌、神经胶质瘤、成神经细胞瘤、肺鳞癌、肺腺癌、膀胱癌、胃癌、结肠癌、大肠癌、肾癌、胆管癌、胃癌、食管鳞癌、卵巢癌、胰腺癌、乳腺癌、前列腺癌、肝癌、脑癌、多发性骨髓瘤、皮肤癌、上皮细胞癌、白血病和宫颈癌等癌症，包括其它远离肿瘤原发部位的组织或器官的转移病变。
下文中提供的实施例和制备例进一步阐明和举例说明本发明化合物及其制备方法。应当理解，下述实例和制备例的范围并不以任何方式限制本发明的范围。
下面的合成路线概括并描述了本发明的通式I化合物的制备，所有的原料都是通过有机化学领域普通技术人员熟知的方法制备或者可商购。本发明的化合物都是通过这些流程中描述的方法或通过与其类似的方法制备的，这些方法是有机化学领域普通技术人员熟知的。这些流程中应用的全部可变因数如权利要求中的定义。
路线一：
以Ceritinib为起始原料，与卤代物在碱的作用下发生取代反应生成中间体A，中间体A与二硫化碳在叔丁醇钾的作用下生成中间体B，中间体B与氯代物反应制得通式I中的目标化合物。
路线二：
以Ceritinib为起始原料，与二卤代物在碱的作用下发生取代反应生成中间体C，中间体C与取代的二硫基氨基甲酸钠反应制得通式I中的目标化合物。
所述的L、X、Y、Ra的定义如权利要求所述，Z指卤素(氯、溴或碘)。本发明的具有通式I的2,4-二芳氨基嘧啶类化合物均可按照上述反应路线描述的方法或类似的方法制备得到。
具体实施方式:
在以下的实施例中，描绘了制备部分所述化合物的方法。应了解，以下方法及所属领域的普通技术人员已知的其他方法均可适用于本发明所述的所有化合物的制备。实施例旨在阐述而不是限制本发明的范围。
实施例1：
2-(二甲氨基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
步骤1：4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸钾盐
将Ceritinib(2g,3.58mmol)溶于40mL THF中，0℃下加入叔丁醇钾(0.48g,3.94mmol)，之后缓慢加入二硫化碳(0.52g,5.37mmol)，室温反应2h。反应完毕，析出固体，抽滤，滤渣用乙醚打浆，得白色固体1.74g，收率72.7％，无需进一步纯化。
步骤2：2-(二甲氨基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
将4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸钾(0.1g,0.15mmol)和2-氯-N,N-二甲基乙胺(0.02g,0.18mmol)溶于2mL DMF中，室温反应1h。反应完毕，加水，析出固体，抽滤，干燥，柱层析分离纯化得白色固体90mg，收率86.2％。
MS(ESI)m/z:705.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.50(d,J＝8.3Hz,1H),8.09(s,1H),7.97(s,1H),7.86(dd,J＝7.9,1.2Hz,1H),7.60–7.52(m,1H),7.48(s,1H),7.19(d,J＝15.1Hz,1H),6.60(s,1H),5.78(s,1H),4.80(s,1H),4.48(hept,J＝6.0Hz,1H),3.48(s,2H),3.26–3.13(m,2H),3.06(s,1H),3.00–2.92(m,1H),2.68(s,2H),2.31(s,6H),2.12(s,3H),1.82(d,J＝12.9Hz,2H),1.65(d,J＝38.7Hz,2H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ195.11,156.40,154.36,154.32,143.70,137.47,134.68,133.61,130.29,127.09,125.93,123.92,122.63,122.14,119.66,109.71,104.91,70.67,64.85,56.79,54.44,51.53,49.89,44.07,37.25,33.89,31.79,31.14,21.23,18.04,14.36.
类似实施例1的合成方法，以4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸钾为原料，与卤代物取代制备得到实施例2-19的化合物。
实施例2：
2-(二乙氨基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:733.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.50(d,J＝8.3Hz,1H),8.09(s,1H),7.97(s,1H),7.86(dd,J＝7.9,1.0Hz,1H),7.56(dd,J＝11.4,4.1Hz,1H),7.48(s,1H),7.19(t,J＝7.5Hz,1H),6.60(s,1H),5.75(s,1H),4.77(s,1H),4.53–4.42(m,1H),3.49(s,2H),3.19(tt,J＝13.6,6.6Hz,2H),3.07(s,1H),3.00–2.93(m,1H),2.84(s,2H),2.69(s,4H),2.12(s,3H),1.83(d,J＝13.0Hz,2H),1.65(s,2H),1.29(d,J＝6.0Hz,6H),1.25(d,J＝6.8Hz,6H),1.09(t,J＝6.3Hz,6H)；13C NMR(151MHz,CDCl3)δ194.99,156.40,154.35,154.31,143.70,137.46,134.66,133.62,130.28,127.11,125.96,123.90,122.62,122.14,119.68,109.73,104.91,70.69,64.84,54.44,51.61,50.33,49.89,45.95,37.24,32.83,31.77,31.10,28.68,21.23,18.04,14.36,10.23。
实施例3：
2-(四氢吡咯-1-基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:731.4[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.98(s,1H),7.87(dd,J＝7.9,1.4Hz,1H),7.58–7.53(m,1H),7.48(s,1H),7.20(d,J＝15.1Hz,1H),6.60(s,1H),5.75(s,1H),4.76(s,1H),4.48(hept,J＝6.0Hz,1H),3.59(s,2H),3.28–3.16(m,2H),3.14–2.44(m,8H),2.12(s,3H),1.83(d,J＝13.5Hz,6H),1.64(s,3H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.95,156.38,154.34,143.69,137.45,134.62,133.59,130.28,127.11,125.93,123.91,122.61,122.12,119.65,109.71,104.92,70.68,54.43,53.73,52.93,37.23,22.50,21.23,18.04,14.35。
实施例4：
2-(哌啶-1-基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:745.4[M+H]+；1H NMR(600MHz,CDCl3)δ9.51(s,1H),8.57(d,J＝8.3Hz,1H),8.16(s,1H),8.04(s,1H),7.93(d,J＝8.0Hz,1H),7.65–7.59(m,1H),7.55(s,1H),7.26(dd,J＝15.2,0.8Hz,1H),6.67(s,1H),5.84(s,1H),4.86(s,1H),4.55(hept,J＝6.0Hz,1H),3.55(s,2H),3.26(dp,J＝13.6,6.8Hz,2H),3.13(s,1H),3.03(tt,J＝12.0,3.5Hz,1H),2.73(s,2H),2.54(s,4H),2.19(s,3H),1.89(d,J＝13.1Hz,2H),1.64(s,6H),1.47(s,2H),1.36(d,J＝6.1Hz,6H),1.32(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ195.27,156.39,154.35,154.30,143.69,137.46,134.68,133.59,130.28,127.09,125.92,123.91,122.61,122.12,119.65,109.71,104.91,70.67,56.55,54.43,53.26,51.60,49.87,37.26,31.80,31.18,28.68,24.59,23.07,21.23,18.04,14.36。
实施例5：
2-吗啉基乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:747.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.98(s,1H),7.87(dd,J＝7.9,1.5Hz,1H),7.60–7.53(m,1H),7.48(s,1H),7.19(dd,J＝15.2,0.9Hz,1H),6.60(s,1H),5.75(s,1H),4.76(s,1H),4.48(hept,J＝6.2Hz,1H),3.70(s,4H),3.51(s,2H),3.27–3.15(m,2H),3.05(dd,J＝11.9,3.5Hz,1H),2.97(tt,J＝12.0,3.4Hz,1H),2.69(s,2H),2.51(s,4H),2.13(s,3H),1.84(d,J＝12.9Hz,2H),1.65(s,2H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ195.04,156.38,154.34,154.31,143.69,137.46,134.61,133.58,130.28,127.13,125.95,123.91,122.60,122.12,119.67,109.73,104.93,70.70,65.79,56.33,54.43,52.38,51.62,49.88,37.25,33.10,31.77,31.11,28.68,21.23,18.04,14.35。
实施例6：
2-(4-甲基哌嗪-1-基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:760.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.98(s,1H),7.87(dd,J＝7.9,1.4Hz,1H),7.60–7.52(m,1H),7.48(s,1H),7.22–7.18(m,1H),6.60(s,1H),5.76(s,1H),4.77(s,1H),4.48(hept,J＝6.1Hz,1H),3.46(s,2H),3.19(dp,J＝13.5,6.6Hz,2H),3.06(s,1H),2.96(tt,J＝11.9,3.3Hz,1H),2.68(t,J＝7.2Hz,3H),2.55(d,J＝54.3Hz,6H),2.29(s,3H),2.13(s,3H),1.83(d,J＝13.0Hz,2H),1.63(s,2H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ195.18,156.39,154.35,154.31,143.69,137.46,134.67,133.59,130.28,127.11,125.94,123.92,122.61,122.12,119.66,109.73,104.93,70.69,55.83,54.44,53.81,51.50,49.81,44.73,37.27,33.28,31.74,31.12,30.91,28.69,28.35,21.23,18.04,14.36。
实施例7：
2-甲氧基乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:692.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.47(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.96(s,1H),7.86(dd,J＝7.9,1.3Hz,1H),7.60–7.50(m,1H),7.20(t,J＝7.6Hz,2H),6.61(s,1H),5.78(s,1H),4.79(s,1H),4.48(hept,J＝6.0Hz,1H),3.64(s,2H),3.55(s,2H),3.33(s,3H),3.25–3.14(m,2H),3.07(s,1H),2.97(tt,J＝12.0,3.4Hz,1H),2.12(s,3H),1.83(d,J＝13.2Hz,2H),1.66(s,2H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.92,156.22,154.35,153.98,143.79,137.38,134.81,130.29,126.96,125.90,123.95,122.63,122.20,119.76,109.72,104.88,70.67,69.75,64.84,57.79,54.46,51.66,49.87,37.26,36.00,31.77,31.15,21.22,18.03,14.35。
实施例8：
2-(二乙氨基)丙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:747.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.98(s,1H),7.86(dd,J＝7.9,1.4Hz,1H),7.59–7.52(m,1H),7.49(s,1H),7.25–7.16(m,1H),6.61(s,1H),5.74(s,1H),4.73(s,1H),4.57–4.42(m,1H),3.43–3.26(m,2H),3.19(tt,J＝13.4,6.6Hz,2H),3.06(s,1H),2.97(ddd,J＝11.7,7.6,3.2Hz,1H),2.87(d,J＝6.1Hz,6H),2.13(s,3H),2.10(d,J＝7.4Hz,2H),1.84(d,J＝12.8Hz,2H),1.65(s,2H),1.29(d,J＝6.0Hz,6H),1.25(d,J＝6.9Hz,6H),1.22(d,J＝7.1Hz,6H)；13C NMR(151MHz,CDCl3)δ195.55,157.32,155.27,155.25,144.64,138.39,135.50,134.53,131.21,128.09,126.90,124.84,123.55,123.07,120.62,110.70,105.86,71.68,55.38,50.50,46.65,38.18,33.95,29.61,24.39,22.15,18.97,15.28,9.60。
实施例9：
2-氨基-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:691.2[M+H]+；1H NMR(600MHz,DMSO-d6)δ9.46(s,1H),8.47(d,J＝7.9Hz,1H),8.25(s,1H),8.05(s,1H),7.84(dd,J＝8.0,1.4Hz,1H),7.64(t,J＝7.4Hz,1H),7.56(d,J＝7.6Hz,1H),7.41–7.33(m,1H),7.17(s,1H),6.85(s,1H),5.54(s,1H),4.69(s,1H),4.62(dq,J＝12.0,6.0Hz,1H),4.02(d,J＝8.7Hz,2H),3.45(td,J＝13.6,6.8Hz,2H),3.26(s,1H),3.10(ddd,J＝11.9,7.6,3.1Hz,1H),2.18(s,3H),1.85(s,2H),1.69(s,2H),1.20(d,J＝6.0Hz,6H),1.16(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ192.48,167.22,156.73,154.19,153.65,145.36,136.78,136.77,133.65,129.72,125.80,125.34,123.28,122.51,122.47,122.41,110.47,103.09,69.39,53.59,50.91,49.27,39.40,38.84,36.06,30.98,30.59,20.67,17.29,13.64。
实施例10：
2-(二甲氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:719.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.52(s,1H),8.49(d,J＝8.3Hz,1H),8.07(s,1H),7.93(s,1H),7.87(dd,J＝7.9,1.5Hz,1H),7.68(s,1H),7.57–7.52(m,1H),7.22(d,J＝7.4Hz,1H),6.62(s,1H),5.71(s,1H),4.82(s,1H),4.50(dt,J＝12.1,6.1Hz,1H),4.27(s,2H),3.30–3.15(m,2H),3.13(s,3H),3.11–3.01(m,1H),2.97(dd,J＝9.5,6.0Hz,1H),2.94(s,3H),2.12(s,3H),1.83(d,J＝13.1Hz,2H),1.74–1.62(m,2H),1.30(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.05,166.29,155.84,154.47,144.02,137.23,135.08,133.62,130.32,126.69,125.82,124.04,123.81,122.68,122.38,119.99,109.72,104.84,70.69,54.52,51.80,50.02,39.95,37.21,36.73,35.05,31.73,31.17,21.21,18.02,14.35。
实施例11：
2-(二乙氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:747.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.46(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.86(dd,J＝7.9,1.1Hz,1H),7.56(dd,J＝17.6,10.4Hz,2H),7.20(t,J＝7.5Hz,1H),6.61(s,1H),5.72(s,1H),4.83(s,1H),4.55–4.44(m,1H),4.28(s,2H),3.46–3.40(m,2H),3.36(dd,J＝13.5,6.6Hz,2H),3.24–3.14(m,2H),3.07(s,1H),2.97(ddd,J＝12.0,8.8,3.4Hz,1H),2.12(s,3H),1.83(d,J＝13.5Hz,2H),1.68(dd,J＝24.9,12.5Hz,2H),1.29(d,J＝6.0Hz,6H),1.25(d,J＝6.9Hz,6H),1.22(d,J＝7.2Hz,3H),1.08(t,J＝7.1Hz,3H)；13C NMR(151MHz,CDCl3)δ195.14,166.25,157.19,155.32,144.78,138.33,137.86,135.75,134.56,131.23,127.88,126.80,124.92,123.61,123.16,120.73,110.65,108.91,105.82,71.60,60.67,59.35,55.41,42.59,41.23,40.89,38.14,29.62,29.17,22.16,18.96,15.29,14.40,12.87。
实施例12：
2-(异丙氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:733.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.47(s,1H),8.48(d,J＝8.3Hz,1H),8.06(s,1H),7.94(s,1H),7.85(dd,J＝8.0,1.5Hz,1H),7.58(s,1H),7.55–7.51(m,1H),7.20–7.17(m,1H),6.58(s,1H),6.53(d,J＝7.7Hz,1H),5.66(s,1H),4.72(s,1H),4.46(hept,J＝6.1Hz,1H),4.04(s,1H),3.96(ddd,J＝14.3,13.2,6.6Hz,2H),3.26(s,1H),3.17(dt,J＝13.7,6.8Hz,1H),3.11(s,1H),2.97(ddd,J＝12.1,8.6,3.5Hz,1H),2.11(s,3H),1.84(d,J＝13.5Hz,2H),1.64(s,2H),1.27(d,J＝6.1Hz,6H),1.23(d,J＝6.9Hz,6H),1.08(d,J＝6.6Hz,6H)；13C NMR(151MHz,CDCl3)δ194.16,166.63,156.02,154.42,153.90,143.91,137.29,134.65,133.59,130.32,126.97,125.93,124.01,122.62,122.30,119.94,109.71,104.93,70.76,54.50,52.50,50.34,40.82,39.12,37.15,31.77,31.25,21.55,21.20,18.03,14.35。
实施例13：
2-(环己氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:773.3[M+H]+；1H NMR(600MHz,DMSO-d6)δ9.47(s,1H),8.47(d,J＝8.0Hz,1H),8.25(s,1H),8.07–8.00(m,2H),7.85(dd,J＝8.0,1.5Hz,1H),7.64(t,J＝7.4Hz,1H),7.56(s,1H),7.39–7.34(m,1H),6.84(s,1H),5.54(s,1H),4.68(s,1H),4.62(dt,J＝12.1,6.0Hz,1H),4.01(d,J＝4.4Hz,2H),3.60–3.39(m,3H),3.26(s,1H),3.14–3.06(m,1H),2.18(s,3H),1.85(s,2H),1.76–1.61(m,6H),1.27–1.12(m,18H)；13C NMR(151MHz,CDCl3)δ194.11,165.65,158.34,155.79,155.25,146.98,138.39,135.24,131.32,127.41,126.95,124.89,124.11,124.00,112.08,104.69,71.00,55.19,48.31,41.34,37.64,32.63,25.57,24.81,22.27,18.87,15.24。
实施例14：
2-(环丁氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:745.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.49(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.96(s,1H),7.87(d,J＝7.0Hz,1H),7.71–7.49(m,2H),7.21(d,J＝7.7Hz,1H),6.90(d,J＝7.7Hz,1H),6.61(s,1H),5.69(s,1H),4.74(s,1H),4.48(dt,J＝12.0,6.0Hz,1H),4.35–4.23(m,1H),4.07(s,1H),3.94(s,1H),3.34–3.05(m,3H),3.02–2.94(m,1H),2.27(dd,J＝16.4,7.6Hz,2H),2.13(s,3H),1.90–1.78(m,4H),1.73–1.60(m,4H),1.29(d,J＝6.0Hz,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ195.12,167.57,157.06,155.34,144.83,138.27,134.52,131.25,129.84,129.80,127.99,126.88,124.94,123.56,123.19,120.86,110.67,105.87,71.71,55.43,53.48,51.29,44.93,39.81,38.08,35.85,32.66,32.14,31.83,30.93,29.62,29.24,27.13,25.46,22.60,22.14,18.96,15.29,15.09,14.04。
实施例15：
2-(环戊氨基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:759.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.51(s,1H),8.50(d,J＝8.2Hz,1H),8.08(s,1H),7.95(s,1H),7.87(d,J＝7.4Hz,1H),7.70–7.45(m,2H),7.21(d,J＝7.6Hz,1H),6.76(d,J＝7.2Hz,1H),6.60(s,1H),5.68(s,1H),4.74(s,1H),4.48(dt,J＝12.0,6.0Hz,1H),4.18–4.09(m,1H),4.05(s,1H),3.95(s,1H),3.35–3.05(m,3H),2.99(t,J＝11.9Hz,1H),2.13(s,3H),1.87(dd,J＝12.3,7.9Hz,4H),1.72–1.58(m,4H),1.54(dd,J＝14.4,7.6Hz,2H),1.37(dd,J＝13.1,4.0Hz,2H),1.29(d,J＝6.0Hz,6H),1.25(d,J＝6.7Hz,6H)；13C NMR(151MHz,CDCl3)δ194.24,167.13,156.07,154.44,143.93,137.29,133.59,130.32,128.90,128.87,126.98,125.94,124.02,122.63,122.31,119.95,109.73,104.93,70.78,54.52,52.52,50.50,50.38,38.97,37.16,31.89,31.73,31.23,28.69,28.31,26.20,22.64,21.68,21.21,18.03,14.36,13.11。
实施例16：
2-吗啉-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:761.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.49(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.87(d,J＝7.9Hz,1H),7.74–7.43(m,2H),7.21(d,J＝7.4Hz,1H),6.61(s,1H),5.69(s,1H),4.80(s,1H),4.50(hept,J＝6.0Hz,1H),4.26(s,2H),3.72–3.67(m,2H),3.62(dq,J＝8.3,4.0Hz,6H),3.26(s,1H),3.19(dp,J＝13.7,6.9Hz,1H),3.08(s,1H),2.97(tt,J＝12.0,3.4Hz,1H),2.12(s,3H),1.84(d,J＝13.0Hz,2H),1.68(d,J＝10.6Hz,2H),1.30(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ193.60,165.13,156.12,154.39,153.79,143.86,137.33,134.73,133.60,130.30,126.94,125.87,123.98,122.64,122.25,119.83,109.69,104.89,70.70,65.77,65.65,54.48,51.95,50.12,45.64,41.64,39.27,37.16,31.73,31.17,21.22,18.03,14.35。
实施例17：
2-氧代-2-硫代吗啉乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:777.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.54(s,1H),8.56(d,J＝8.3Hz,1H),8.16(s,1H),8.02(s,1H),7.93(d,J＝7.8Hz,1H),7.62(t,J＝7.5Hz,2H),7.27(d,J＝7.7Hz,1H),6.67(s,1H),5.76(s,1H),4.86(s,1H),4.61–4.51(m,1H),4.35(s,2H),4.01–3.82(m,4H),3.33(s,1H),3.29–3.22(m,1H),3.15(s,1H),3.08–2.99(m,1H),2.79–2.70(m,2H),2.68–2.61(m,2H),2.19(s,3H),1.91(d,J＝12.8Hz,2H),1.75(s,2H),1.36(d,J＝6.0Hz,6H),1.32(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ193.59,164.89,156.10,154.40,153.70,143.90,137.32,134.75,133.60,130.30,126.88,125.86,123.99,122.64,122.27,119.88,109.69,104.90,70.69,54.49,52.00,50.09,48.01,44.10,39.87,37.18,31.80,31.15,26.92,26.33,21.22,18.03,14.35。
实施例18：
2-氧代-2-(哌啶-1-基)乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:759.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.48(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.87(dd,J＝8.0,1.5Hz,1H),7.65–7.49(m,2H),7.21(d,J＝7.3Hz,1H),6.61(s,1H),5.71(s,1H),4.82(s,1H),4.50(hept,J＝6.0Hz,1H),4.29(s,2H),3.55–3.47(m,4H),3.33–3.01(m,3H),2.97(tt,J＝12.0,3.5Hz,1H),2.12(s,3H),1.83(d,J＝13.1Hz,2H),1.68(d,J＝11.1Hz,2H),1.62–1.56(m,4H),1.51(s,2H),1.29(d,J＝6.1Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.10,164.41,156.15,154.40,153.98,143.88,137.35,134.85,133.63,130.31,126.90,125.86,123.99,122.67,122.27,119.82,109.71,104.88,70.67,54.48,51.77,50.07,46.33,42.42,40.40,37.21,31.72,31.15,25.49,24.50,23.44,21.22,18.03,14.36。
实施例19：
2-(4-甲基哌啶-1-基)-2-氧代乙基4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-碳二硫酸酯
MS(ESI)m/z:773.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.51(s,1H),8.49(d,J＝8.3Hz,1H),8.07(s,1H),7.93(s,1H),7.87(dd,J＝7.9,1.1Hz,1H),7.80–7.50(m,2H),7.21(d,J＝7.6Hz,1H),6.61(s,1H),5.71(s,1H),4.82(s,1H),4.54–4.45(m,2H),4.29(q,J＝15.1Hz,2H),3.96(d,J＝13.5Hz,1H),3.31–3.15(m,2H),3.12–3.02(m,2H),2.97(tt,J＝11.9,3.2Hz,1H),2.56(td,J＝12.9,2.5Hz,1H),2.12(s,3H),1.83(d,J＝12.9Hz,2H),1.75–1.60(m,4H),1.30(d,J＝6.0Hz,6H),1.25(d,J＝6.8Hz,6H),1.21–1.12(m,2H),1.06(ddd,J＝24.4,12.6,4.2Hz,1H),0.90(s,3H)；13C NMR(151MHz,CDCl3)δ194.07,164.40,156.02,154.43,153.34,143.94,137.27,134.96,133.61,130.30,126.78,125.83,124.01,122.67,122.32,119.91,109.71,104.85,70.67,54.50,51.80,50.04,45.58,41.79,40.42,37.21,33.62,32.68,31.70,31.14,30.00,21.21,20.68,18.02,14.35。
实施例20：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基二硫代氨基甲酸二乙酯
步骤1：2-氯-1-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1)乙烷-1-酮
将Ceritinib(2g,3.58mmol)溶于20mL干燥二氯甲烷中，0℃下加入三乙胺(0.54g,5.37mmol)，之后缓慢滴加氯乙酰氯(0.44g,3.94mmol)的二氯甲烷溶液，室温反应2h。反应完毕，加水，二氯甲烷萃取，合并有机相，有机层依次用水和饱和食盐水洗涤，无水硫酸钠干燥，抽滤，滤液减压蒸干得淡黄色固体1.95g，收率86.2％，无需进一步纯化。MS(ESI)m/z:634.3[M+H]+。
步骤2：2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基二硫代氨基甲酸二乙酯
2-氯-1-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1)乙烷-1-酮(0.1g,0.16mmol)和二乙基二硫代氨基甲酸钠盐(0.033g,0.19mmol)溶于2mL DMF中，室温反应1h。反应完毕，加水，析出固体，抽滤，干燥，柱层析分离纯化得白色固体79mg，收率67.2％。
MS(ESI)m/z:746.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.49(s,1H),8.50(d,J＝8.3Hz,1H),8.07(s,1H),7.92(s,1H),7.87(dd,J＝8.0,1.6Hz,1H),7.72–7.46(m,2H),7.21(d,J＝8.1Hz,1H),6.64(s,1H),4.73(d,J＝13.3Hz,1H),4.50(hept,J＝6.1Hz,1H),4.37(d,J＝15.1Hz,1H),4.23(d,J＝15.1Hz,1H),4.13(d,J＝13.7Hz,1H),3.96(q,J＝6.8Hz,2H),3.74(q,J＝7.1Hz,2H),3.24–3.11(m,2H),2.87(ddd,J＝12.0,7.7,3.1Hz,1H),2.64(td,J＝12.9,2.2Hz,1H),2.11(s,3H),1.77(dd,J＝38.1,13.1Hz,2H),1.66(qd,J＝12.8,4.0Hz,1H),1.57(qd,J＝12.8,4.2Hz,1H),1.30(t,J＝6.3Hz,6H),1.26(t,J＝7.5Hz,9H),1.21(t,J＝7.1Hz,3H)；13C NMR(151MHz,CDCl3)δ193.27,164.80,156.11,154.41,153.74,143.91,137.31,135.79,133.63,130.29,126.56,125.70,123.98,122.68,122.28,119.86,109.76,104.79,70.56,54.49,48.89,46.19,45.97,42.44,40.07,37.20,32.28,31.27,21.27,21.20,17.96,14.36,11.52,10.52。
类似实施20的合成方法，以Ceritinib为起始原料，与二氯代物在碱的作用下发生取代反应生成关键中间体，再与取代的二硫基氨基甲酸钠盐反应制得制得实施例21-35的化合物。
实施例21：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基四氢吡咯-1-碳二硫酸酯
MS(ESI)m/z:745.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.86(d,J＝7.9Hz,1H),7.80–7.50(m,2H),7.20(d,J＝15.2Hz,1H),6.64(s,1H),4.73(d,J＝12.4Hz,1H),4.50(hept,J＝6.0Hz,1H),4.38(d,J＝15.2Hz,1H),4.26(d,J＝15.3Hz,1H),4.14(d,J＝12.9Hz,1H),3.86(t,J＝6.9Hz,2H),3.70–3.62(m,2H),3.19(td,J＝13.6,7.0Hz,2H),2.85(dt,J＝11.9,3.2Hz,1H),2.64(t,J＝12.0Hz,1H),2.11(s,3H),2.03(dd,J＝13.7,6.8Hz,2H),1.92(p,J＝7.0Hz,2H),1.77(dd,J＝39.0,13.1Hz,2H),1.66(ddd,J＝25.3,12.7,3.8Hz,1H),1.57(ddd,J＝25.3,12.7,3.9Hz,1H),1.30(t,J＝6.9Hz,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ190.44,164.77,156.36,154.32,154.21,143.75,137.41,135.56,133.63,130.27,126.74,125.73,123.91,122.66,122.16,119.68,109.75,104.80,70.57,54.44,54.29,49.69,46.18,42.48,39.37,37.19,32.28,31.24,25.13,23.31,21.29,21.21,17.97,14.36。
实施例22：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基4-甲基哌嗪-1-碳二硫酸酯
MS(ESI)m/z:774.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.51(d,J＝8.2Hz,1H),8.09(s,1H),7.96(s,1H),7.86(dd,J＝8.0,1.5Hz,1H),7.58–7.52(m,1H),7.48(s,1H),7.19(dd,J＝15.3,1.0Hz,1H),6.64(s,1H),4.73(d,J＝13.2Hz,1H),4.49(hept,J＝6.0Hz,1H),4.44–4.18(m,4H),4.12(d,J＝13.5Hz,1H),3.97(s,2H),3.24–3.13(m,2H),2.86(tt,J＝12.0,3.3Hz,1H),2.65(td,J＝12.9,2.1Hz,1H),2.47(s,4H),2.28(s,3H),2.11(s,3H),1.77(dd,J＝41.6,13.0Hz,2H),1.65(qd,J＝12.8,4.0Hz,1H),1.57(qd,J＝12.8,4.2Hz,1H),1.32–1.27(m,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.78,164.50,156.42,154.35,154.31,143.70,137.46,135.42,133.61,130.27,126.84,125.77,123.90,122.65,122.12,119.64,109.73,104.84,70.58,54.43,53.29,50.31,48.81,46.17,44.52,42.48,40.07,40.07,37.18,32.30,31.25,21.30,21.22,17.98,14.36。
实施例23：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基吗啉-4-碳二硫酸酯
MS(ESI)m/z:761.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.48(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.94(s,1H),7.87(dd,J＝7.9,1.5Hz,1H),7.66–7.49(m,2H),7.20(t,J＝7.5Hz,1H),6.64(s,1H),4.73(d,J＝13.3Hz,1H),4.49(hept,J＝6.0Hz,1H),4.39(d,J＝15.4Hz,1H),4.20(dd,J＝91.7,14.4Hz,4H),3.97(s,2H),3.75–3.66(m,4H),3.25–3.15(m,2H),2.87(tt,J＝12.0,3.3Hz,1H),2.65(td,J＝12.8,1.8Hz,1H),1.30(dd,J＝7.4,6.4Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ195.35,164.37,156.15,154.39,153.73,143.87,137.34,135.62,133.62,130.29,126.66,125.76,123.97,122.66,122.25,119.84,109.77,104.83,70.61,65.27,65.10,54.48,50.59,49.54,46.16,42.50,39.90,37.18,32.29,31.24,21.28,21.21,17.97,14.36。
实施例24：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基4-(甲磺酰基)哌嗪-1-碳二硫酸酯
MS(ESI)m/z:838.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.52(s,1H),8.50(d,J＝8.3Hz,1H),8.07(s,1H),7.93(s,1H),7.87(d,J＝7.9Hz,1H),7.66(s,1H),7.57–7.51(m,1H),7.21(d,J＝7.5Hz,1H),6.64(s,1H),4.73(d,J＝13.0Hz,1H),4.56–4.45(m,1H),4.43–3.95(m,7H),3.29(s,4H),3.25–3.15(m,2H),2.91–2.83(m,1H),2.75(s,3H),2.66(t,J＝12.0Hz,1H),2.12(s,3H),1.79(dd,J＝44.0,13.0Hz,2H),1.66(ddd,J＝25.3,12.7,3.7Hz,1H),1.57(ddd,J＝25.6,12.9,4.0Hz,1H),1.30(dd,J＝8.0,6.3Hz,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ196.08,164.07,156.18,154.38,153.86,143.84,137.36,135.50,133.61,130.30,126.75,125.80,123.95,122.64,122.23,119.83,109.78,104.87,70.65,54.48,52.44,49.12,49.07,46.15,44.25,42.54,40.28,37.15,34.12,32.29,31.23,21.22,17.98,14.36。
实施例25：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基3,4,5-三甲基哌嗪-1-碳二硫酸酯
MS(ESI)m/z:802.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.96(s,1H),7.86(d,J＝7.8Hz,1H),7.56(t,J＝7.8Hz,1H),7.48(s,1H),7.19(d,J＝14.9Hz,1H),6.64(s,1H),4.73(d,J＝13.0Hz,1H),4.50(td,J＝12.0,5.9Hz,2H),4.33(dd,J＝66.3,15.1Hz,2H),4.12(d,J＝12.1Hz,1H),3.19(dd,J＝13.7,7.2Hz,2H),2.94–2.53(m,6H),1.30(t,J＝6.7Hz,6H),1.25(d,J＝6.8Hz,6H),1.18(s,3H),1.09(s,6H)；13C NMR(151MHz,CDCl3)δ194.24,164.52,156.40,154.33,154.28,143.68,137.44,135.40,133.59,130.24,126.82,125.75,123.88,122.62,122.09,119.61,109.72,104.82,70.55,66.72,65.15,63.84,56.62,55.39,54.41,49.79,49.50,46.15,42.44,42.28,40.06,37.86,37.14,32.27,31.22,29.47,28.66,27.95,22.94,21.93,21.27,21.19,17.95,14.34。
实施例26：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基4-(2-羟乙基)哌嗪-1-碳二硫酸酯
MS(ESI)m/z:804.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.96(s,1H),7.86(dd,J＝7.9,1.4Hz,1H),7.59–7.53(m,1H),7.48(s,1H),7.20(d,J＝15.1Hz,1H),6.64(s,1H),4.73(d,J＝13.1Hz,1H),4.53–4.45(m,1H),4.41–3.94(m,7H),3.69–3.59(m,2H),3.24–3.15(m,2H),2.92–2.84(m,1H),2.64(dd,J＝25.3,19.8Hz,8H),2.11(s,3H),1.78(dd,J＝42.1,12.9Hz,2H),1.65(ddd,J＝25.5,12.8,3.8Hz,1H),1.57(ddd,J＝16.5,13.0,4.2Hz,1H),1.32–1.28(m,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ195.02,164.40,156.41,154.34,154.31,143.71,137.46,135.39,133.61,130.27,126.86,125.79,123.90,122.64,122.12,119.65,109.74,104.86,70.59,58.23,56.76,54.43,51.33,49.93,48.61,46.17,42.50,40.12,37.16,32.30,31.24,28.69,21.30,21.22,17.98,14.36。
实施例27：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基二硫代氨基甲酸环丙酯
MS(ESI)m/z:731.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.59(s,1H),9.48(s,1H),8.50(d,J＝8.2Hz,1H),8.08(s,1H),7.95(s,1H),7.86(d,J＝7.7Hz,1H),7.68–7.50(m,1H),7.21(s,1H),6.62(s,1H),4.71(dd,J＝35.9,12.5Hz,1H),4.56–4.44(m,1H),4.41–4.04(m,1H),3.91–3.72(m,2H),3.32–3.10(m,3H),2.85(d,J＝11.4Hz,1H),2.67(dd,J＝22.6,10.6Hz,1H),2.11(s,3H),1.78(dd,J＝32.1,15.9Hz,2H),1.67–1.49(m,2H),1.30(t,J＝5.0Hz,6H),1.25(d,J＝6.7Hz,6H),0.88(dd,J＝19.7,5.9Hz,2H),0.73(d,J＝15.9Hz,2H)；13C NMR(151MHz,CDCl3)δ194.56,166.78,156.15,154.37,153.76,143.85,137.34,135.06,133.62,130.28,126.87,125.79,123.92,122.63,122.24,119.83,109.73,104.87,70.70,54.48,46.61,46.17,42.42,36.98,35.50,31.99,31.17,21.26,21.17,17.99,14.35,5.85,5.82。
实施例28：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基哌啶-1-碳二硫酸酯
MS(ESI)m/z:759.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.44(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.86(d,J＝7.9Hz,1H),7.55(t,J＝7.8Hz,1H),7.51(s,1H),7.20(d,J＝14.7Hz,1H),6.64(s,1H),4.73(d,J＝12.0Hz,1H),4.53–4.44(m,1H),4.38(d,J＝15.0Hz,1H),4.30–4.17(m,3H),4.14(d,J＝12.9Hz,1H),3.88(s,2H),3.24–3.13(m,2H),2.90–2.82(m,1H),2.64(t,J＝12.5Hz,1H),2.11(s,3H),1.77(dd,J＝39.7,12.9Hz,2H),1.69–1.52(m,8H),1.30(t,J＝6.0Hz,6H),1.25(dd,J＝6.8,1.9Hz,6H)；13CNMR(151MHz,CDCl3)δ193.22,164.76,156.33,154.30,154.15,143.73,137.40,135.55,133.60,130.25,126.71,125.72,123.88,122.64,122.14,119.66,109.73,104.78,70.54,54.42,52.28,50.52,46.16,42.42,40.02,37.17,32.27,31.24,25.03,24.41,23.19,21.27,21.19,17.95,14.34。
实施例29：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基硫代吗啉-4-碳二硫酸酯
MS(ESI)m/z:777.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.48(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.94(s,1H),7.86(dd,J＝7.9,1.5Hz,1H),7.56(dt,J＝8.6,5.8Hz,2H),7.22–7.19(m,1H),6.64(s,1H),4.73(d,J＝13.3Hz,1H),4.62–4.42(m,3H),4.41–4.19(m,4H),4.12(d,J＝13.5Hz,1H),3.24–3.15(m,2H),2.87(tt,J＝11.9,3.2Hz,1H),2.73–2.68(m,4H),2.68–2.62(m,1H),2.11(s,3H),1.78(dd,J＝42.8,13.0Hz,2H),1.69–1.61(m,1H),1.57(qd,J＝12.8,4.1Hz,1H),1.32–1.28(m,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ194.63,164.34,156.23,154.36,153.88,143.81,137.37,135.53,133.61,130.28,126.72,125.76,123.94,122.65,122.20,119.77,109.75,104.83,70.60,54.46,53.71,52.43,46.14,42.46,40.24,37.17,32.29,31.23,26.33,26.19,21.28,21.21,17.97,14.35。
实施例30：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基4-乙基哌嗪-1-碳二硫酸酯
MS(ESI)m/z:788.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.51(d,J＝8.3Hz,1H),8.09(d,J＝1.5Hz,1H),7.96(s,1H),7.86(d,J＝7.9Hz,1H),7.56(t,J＝7.8Hz,1H),7.48(s,1H),7.19(d,J＝15.2Hz,1H),6.63(s,1H),4.73(d,J＝12.3Hz,1H),4.55–4.44(m,1H),4.32(dd,J＝65.8,15.3Hz,4H),4.12(d,J＝13.5Hz,1H),3.98(s,2H),3.19(dd,J＝13.6,8.4Hz,2H),2.86(t,J＝11.9Hz,1H),2.65(t,J＝12.6Hz,1H),2.58–2.36(m,6H),2.11(s,3H),1.77(dd,J＝41.5,13.0Hz,2H),1.65(ddd,J＝25.4,12.7,3.7Hz,1H),1.56(ddd,J＝16.1,12.8,3.8Hz,1H),1.30(t,J＝6.6Hz,6H),1.25(d,J＝6.8Hz,6H),1.06(s,3H)；13CNMR(151MHz,CDCl3)δ194.57,164.50,156.40,154.33,154.28,143.68,137.44,135.41,133.59,130.24,126.81,125.74,123.88,122.62,122.09,119.61,109.71,104.81,70.55,54.41,51.01,50.88,50.32,48.85,46.15,42.46,40.00,37.15,32.27,31.22,28.66,21.27,21.19,17.95,14.34,10.82。
实施例31：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基4-环戊基哌嗪-1-碳二硫酸酯
MS(ESI)m/z:828.4[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.96(s,1H),7.86(dd,J＝7.9,0.9Hz,1H),7.59–7.52(m,1H),7.48(s,1H),7.19(d,J＝15.1Hz,1H),6.64(s,1H),4.73(d,J＝13.2Hz,1H),4.57–4.44(m,1H),4.40–4.18(m,4H),4.13(d,J＝13.3Hz,1H),3.97(s,2H),3.25–3.14(m,2H),3.25–3.14(m,2H),2.86(ddd,J＝12.0,8.9,3.3Hz,1H),2.70–2.40(m,6H),2.11(s,3H),1.81(d,J＝11.2Hz,3H),1.76–1.43(m,9H),1.30(t,J＝6.8Hz,6H),1.25(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ194.40,164.53,156.42,154.36,154.31,143.70,137.46,135.43,133.61,130.27,126.83,125.77,123.90,122.65,122.12,119.63,109.73,104.84,70.58,66.03,54.43,50.77,50.56,50.54,48.79,46.18,42.48,40.00,37.18,32.30,31.25,29.29,28.69,23.03,21.30,21.22,17.97,14.36。
实施例32：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基3-甲基哌嗪-1-碳二硫酸酯
MS(ESI)m/z:774.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.51(d,J＝8.3Hz,1H),8.09(s,1H),7.96(s,1H),7.86(d,J＝7.1Hz,1H),7.56(t,J＝7.4Hz,1H),7.48(s,1H),7.19(d,J＝14.9Hz,1H),6.64(s,1H),4.73(d,J＝12.8Hz,1H),4.49(dt,J＝12.0,6.0Hz,1H),4.38(dd,J＝15.2,5.1Hz,1H),4.27(dd,J＝15.2,5.2Hz,1H),4.13(d,J＝13.0Hz,1H),3.24–3.16(m,2H),3.05(d,J＝12.4Hz,1H),2.86(dd,J＝13.2,10.0Hz,3H),2.65(t,J＝12.1Hz,1H),2.21(s,1H),2.11(s,3H),1.84–1.72(m,2H),1.70–1.52(m,2H),1.30(t,J＝6.6Hz,6H),1.25(d,J＝6.8Hz,6H),1.09(d,J＝5.7Hz,3H)；13C NMR(151MHz,CDCl3)δ194.54,164.53,156.41,154.34,154.30,143.71,137.45,135.42,133.62,130.26,126.83,125.78,123.88,122.64,122.12,119.65,109.75,104.83,70.59,54.43,50.68,49.77,49.41,46.17,42.49,40.01,37.16,32.28,31.24,28.68,21.29,21.21,17.97,14.35,13.12。
实施例33：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基硫代吗啉-4-碳二硫酸酯1,1-二氧化物
MS(ESI)m/z:809.2[M+H]+；1H NMR(600MHz,CDCl3)δ9.50(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.94(s,1H),7.87(dd,J＝8.0,1.5Hz,1H),7.67–7.50(m,2H),7.22–7.20(m,1H),6.63(s,1H),4.72(d,J＝13.3Hz,1H),4.59(s,4H),4.47(dd,J＝12.2,6.1Hz,1H),4.31(dd,J＝46.8,15.6Hz,2H),4.09(d,J＝13.6Hz,1H),3.25–3.16(m,2H),3.15–3.11(m,4H),2.88(tt,J＝12.0,3.3Hz,1H),2.67(td,J＝12.9,2.0Hz,1H),2.12(s,3H),1.84(d,J＝14.1Hz,1H),1.76(d,J＝13.1Hz,1H),1.69–1.62(m,1H),1.60–1.52(m,1H),1.32–1.29(m,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ197.45,163.55,156.25,154.35,154.01,143.79,137.39,135.31,133.60,130.29,126.85,125.83,123.93,122.61,122.18,119.78,109.75,104.89,70.65,54.46,50.52,47.32,46.10,42.54,41.38,37.12,32.28,31.20,28.09,28.04,21.29,21.21,17.98,14.35。
实施例34：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基(2-(二甲氨基)乙基)(甲基)碳二硫酸酯
MS(ESI)m/z:776.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.43(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.95(s,1H),7.85(d,J＝7.9Hz,1H),7.55(t,J＝7.8Hz,1H),7.48(s,1H),7.18(d,J＝7.6Hz,1H),6.64(s,1H),4.72(d,J＝12.8Hz,1H),4.49(dt,J＝12.0,6.0Hz,1H),4.34(d,J＝15.3Hz,1H),4.21(d,J＝15.2Hz,1H),4.17–4.08(m,2H),3.86(d,J＝6.2Hz,1H),3.46(s,1H),3.37(s,2H),3.23–3.14(m,2H),2.90–2.82(m,1H),2.61(ddd,J＝21.0,19.2,9.9Hz,3H),2.25(d,J＝16.8Hz,6H),2.11(s,3H),1.80(d,J＝12.9Hz,1H),1.73(d,J＝12.9Hz,1H),1.66(ddd,J＝25.3,12.7,3.5Hz,1H),1.56(ddd,J＝16.3,12.8,4.0Hz,1H),1.29(t,J＝6.7Hz,6H),1.24(d,J＝6.8Hz,6H)；13C NMR(151MHz,CDCl3)δ195.36,164.54,156.41,154.34,154.28,143.69,137.44,135.47,133.62,130.24,126.78,125.74,123.86,122.63,122.11,119.63,109.72,104.79,70.53,55.07,54.42,54.25,53.89,46.17,44.65,44.48,42.47,40.41,37.16,32.26,31.25,21.29,21.21,17.97,14.35。
实施例35：
2-(4-(4-((5-氯-4-((2-(异丙磺酰基)苯基)氨基)嘧啶-2-基)氨基)-5-异丙氧基-2-甲基苯基)哌啶-1-基)-2-氧代乙基(S)-2-(羟甲基)四氢吡咯-1-碳二硫酸酯
MS(ESI)m/z:775.3[M+H]+；1H NMR(600MHz,CDCl3)δ9.47(s,1H),8.50(d,J＝8.3Hz,1H),8.08(s,1H),7.94(s,1H),7.86(dd,J＝7.9,1.5Hz,1H),7.63–7.49(m,2H),7.20(t,J＝7.6Hz,1H),6.64(s,1H),4.83(s,1H),4.72(d,J＝12.3Hz,1H),4.53–4.45(m,1H),4.35(dt,J＝17.2,8.7Hz,1H),4.27–4.18(m,1H),4.12(d,J＝13.2Hz,1H),3.92–3.68(m,4H),3.19(dt,J＝13.7,6.8Hz,2H),2.87(t,J＝11.2Hz,1H),2.71–2.60(m,2H),2.15(d,J＝7.7Hz,1H),2.11(s,3H),2.07–1.96(m,3H),1.80(d,J＝13.1Hz,1H),1.74(d,J＝13.1Hz,1H),1.66(dd,J＝20.7,7.9Hz,1H),1.57(qd,J＝12.7,3.8Hz,1H),1.30(t,J＝6.6Hz,6H),1.25(d,J＝6.9Hz,6H)；13C NMR(151MHz,CDCl3)δ192.95,164.53,156.20,154.36,153.86,143.83,137.36,135.60,133.62,130.27,126.67,125.73,123.93,122.66,122.22,119.78,109.76,104.81,70.59,62.59,62.40,54.47,46.18,42.56,39.45,37.16,32.23,31.24,28.68,26.72,23.11,21.28,21.21,17.97,14.35。
本发明化合物生物学活性研究
体外抗肿瘤细胞活性
对按照本发明的通式I的2,4-二芳氨基嘧啶类化合物进行了体外抑制人间变性大细胞淋巴瘤细胞Karpas299和人非小细胞肺癌细胞H2228活性的试验。
Karpas299细胞用CCK-8法进行测试。将处于对数生长期的细胞以6×104个/mL接种至96孔板中，细胞液体积为100μL/孔。向每孔加入100μL 5个不同浓度的药液，每个浓度设置四个复孔，于标准条件下孵育72h。孵育结束后取出96孔板，每孔加入20μL的CCK-8溶液，继续孵育4h后取出，置于微量振荡仪上振荡5min。在酶标仪上于450nm测得各孔的吸光度(OD)。
H2228细胞用MTT法进行测试。将处于对数生长期的细胞以1×104个/mL接种至96孔板中，细胞悬浮液体积为100μL/孔，置于标准条件下培养。24h后，每孔加入100μL 5个用培养液配制的不同浓度药液，每个浓度设置四个复孔，于标准条件下孵育96h。孵育结束后取出96孔板，每孔加入50μL的MTT溶液(2mg/mL)，继续孵育4h后取出，甩板弃去上清液后每孔加100μL的DMSO溶液，并置于微量振荡仪上振荡5min，使结晶物完全溶解。在酶标仪上于570nm测得各孔的吸光度(OD)。
按公式计算细胞体外增殖的抑制率(Inhibition Rate,IR)：
IR％＝(ODcontrol-ODsample)/(ODcontrol-ODblank)×100％
式中，ODcontrol：未加药孔的OD值；ODsample：加药孔的OD值；ODblank：在CCK-8法中为只加培养基孔的OD值，在MTT法中为只加DMSO孔的OD值。
最后，用SPSS软件输入数据并绘制抑制率-浓度曲线计算IC50。
化合物的抑制Karpas299和H2228细胞活性结果见表1。
表1
ALKWT、ALKL1196M和ALKG1202R酶活性试验
用于测量ALK酶活性的试验基于酶联免疫吸附试验。具体操作如下：室温下，在0.25mg/mL PGT包被的板上,将实施例化合物、50pM ALK和5μM ATP在试验缓冲液中(25mMMOPS,pH＝7.4,1mM DTT,5mM MgCl2,1mM MnCl2,0.1％NaN3)温育20min。通过冲洗除去反应混合液并用0.2μg/mL缀合辣根过氧化酶的磷酸酪氨酸特异性克隆抗体检测磷酸聚合物底物。加入1M磷酸终止显色后，于450nm处通过分光光度法定量显色的底物颜色。
部分实施例化合物对ALKWT、ALKL1196M和ALKG1202R酶的抑制数据见表2。
表2
从上述试验结果可以清楚地看出，本发明中通式I的化合物对Karpas299和H2228细胞具有较好的抗增殖活性，部分化合物对ALKWT、ALKL1196M和ALKG1202R酶具有显著的抑制活性。
Claims (5)
1.2,4-二芳氨基嘧啶类化合物或其立体异构体或其药学上可接受的盐，其中化合物具有下述化学结构式I或II：
2.权利要求1所述的2,4-二芳氨基嘧啶类化合物或其立体异构体或其药学上可接受的盐，所述的药学上可接受的盐包括与无机酸、有机酸、碱金属离子形成的盐；所述的无机酸选自：盐酸、氢溴酸、氢氟酸、硫酸、磷酸；所述的有机酸选自：琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、甲磺酸、乙磺酸或对甲苯磺酸；所属的碱金属离子选自锂离子、钠离子或钾离子。
3.一种药物组合物，其特征在于，包含权利要求1或2中的化合物或其立体异构体、或其药学上可接受的盐作为活性成分以及药学上可接受的赋形剂。
4.权利要求1或2中的化合物或其立体异构体、或其药学上可接受的盐或权利要求3所述的药物组合物在制备ALK激酶抑制剂中的用途。
5.权利要求1或2中的化合物或其立体异构体、或其药学上可接受的盐或权利要求3所述的药物组合物在制备抗肿瘤药物中的用途，其特征在于，所述的肿瘤选自为淋巴瘤、非小细胞肺癌、小细胞肺癌、头颈部细胞癌、神经胶质瘤、成神经细胞瘤、肺鳞癌、肺腺癌、膀胱癌、胃癌、结肠癌、大肠癌、肾癌、胆管癌、胃癌、食管鳞癌、卵巢癌、胰腺癌、乳腺癌、前列腺癌、肝癌、脑癌、多发性骨髓瘤、皮肤癌、上皮细胞癌、白血病和宫颈癌中的任一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210475888.9A CN114805301B (zh) | 2022-04-29 | 2022-04-29 | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210475888.9A CN114805301B (zh) | 2022-04-29 | 2022-04-29 | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114805301A CN114805301A (zh) | 2022-07-29 |
| CN114805301B true CN114805301B (zh) | 2024-04-05 |
Family
ID=82510819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210475888.9A Active CN114805301B (zh) | 2022-04-29 | 2022-04-29 | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114805301B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102131788A (zh) * | 2008-04-07 | 2011-07-20 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN110548151A (zh) * | 2018-06-01 | 2019-12-10 | 四川大学 | 一种共价药物的设计方法 |
-
2022
- 2022-04-29 CN CN202210475888.9A patent/CN114805301B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102131788A (zh) * | 2008-04-07 | 2011-07-20 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CN110548151A (zh) * | 2018-06-01 | 2019-12-10 | 四川大学 | 一种共价药物的设计方法 |
Non-Patent Citations (1)
| Title |
|---|
| 孟繁森.药物化学.中国医药科技出版社,2016,386. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114805301A (zh) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104936951B (zh) | 作为激酶抑制剂的苯并咪唑衍生物 | |
| CN107698603B (zh) | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 | |
| CA2488739A1 (en) | Nitrogen-containing aromatic derivatives | |
| JP2010505859A (ja) | タンパク質キナーゼ阻害剤およびそれを使用するための方法 | |
| JP6518690B2 (ja) | （５，６−ジヒドロ）ピリミド［４，５−ｅ］インドリジン | |
| KR20090118601A (ko) | 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물 | |
| JP2013534221A (ja) | Ａｌｋ阻害剤としての４−（１ｈ−インドール−３−イル）−ピリミジン | |
| BR112016003247B1 (pt) | Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso | |
| CN105452257A (zh) | 新型稠合嘧啶化合物或其盐 | |
| JP7323896B2 (ja) | カゼインキナーゼ１ε阻害剤、医薬組成物及びその使用 | |
| CN101827525A (zh) | 激酶抑制剂化合物 | |
| CN105315285A (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
| US20200361908A1 (en) | Crystals of aniline pyrimidine compound serving as egfr inhibitor | |
| JP2022547294A (ja) | キナーゼ阻害剤としての３，５－ジ置換ピラゾール化合物およびその応用 | |
| JPWO2006008874A1 (ja) | アミノチアゾ−ル骨格を有するＣｄｋ４、６選択的阻害剤 | |
| CN109575045B (zh) | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 | |
| CN101265274B (zh) | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 | |
| CN114805301B (zh) | 2,4-二芳氨基嘧啶类化合物及其制备方法和应用 | |
| CA3188077A1 (en) | Egfr inhibitor, preparation method therefor and application thereof | |
| CN111253370B (zh) | N-多取代吡啶-2-氨基嘧啶类衍生物及用途 | |
| WO2004080979A1 (en) | Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives | |
| CN114380806B (zh) | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 | |
| CN111732597A (zh) | 含4-酰胺苯氧基的2-氨基嘧啶杂环类化合物的制备及应用 | |
| WO2020172906A1 (zh) | 一种新型pan-RAF激酶抑制剂及其用途 | |
| CN116969923A (zh) | 杂芳基氨基化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |